

해외 바이오의약품 임상 현황 (2020.06.01~2020.06.07)

한국바이오의약품협회, 2020.6.9.
출처: ClinicalTrials.gov

○ 미국 84건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04364178	Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV	Adenovirus Cytomegalovirus Infections Epstein-Barr Virus Infections	Biological: Adenovirus Specific T-Lymphocytes Biological: Cytomegalovirus Specific T-Lymphocytes Biological: Epstein-Barr Virus Specific T-Lymphocytes	Jessie Barnum University of Pittsburgh	Phase 1 Phase 2
NCT04314843	Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma	Relapsed/Refractory Large B-cell Lymphoma	Drug: Cyclophosphamide Drug: Fludarabine Biological: Lenzilumab Biological: Axicabtagene Ciloleucel	Kite, A Gilead Company Humanigen, Inc. Gilead Sciences	Phase 1 Phase 2
NCT04257578	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma	B-Cell Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Primary Mediastinal (Thymic) Large B-Cell Lymphoma Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Drug: Acalabrutinib Biological: Axicabtagene Ciloleucel	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 1 Phase 2
NCT04201821	Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women	Fecal Incontinence	Biological: fecal microbial transplantation (FMT)	University of Pennsylvania	Phase 1 Phase 2
NCT04129515	NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis	Metastatic Melanoma Melanoma Brain Metastasis	Device: NovoTTF-200A Drug: Pembrolizumab	Eric Wong, MD Dana-Farber Cancer Institute	Phase 1 Phase 2
NCT04418518	A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness	COVID-19	Biological: Convalescent plasma	Weill Medical College of Cornell University Hamilton Health Sciences Corporation	Phase 3
NCT04416568	Study of Nivolumab and Ipilimumab in Children and Young Adults With IN1-Negative Cancers	Malignant Rhabdoid Tumor Rhabdoid Tumor of the Kidney Epithelioid Sarcoma Chordoma (Poorly Differentiated or De-differentiated) Atypical Teratoid/Rhabdoid Tumor Other IN1 Negative Malignant Tumors (With PI Approval)	Drug: Nivolumab Drug: Ipilimumab	Dana-Farber Cancer Institute	Phase 2
NCT04415749	NasoShield in Healthy Adults to Study Safety and Immunogenicity	Healthy Volunteers	Biological: NasoShield Other: Placebo	Altimmune, Inc. Biomedical Advanced Research and Development Authority	Phase 1
NCT04412772	A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS	COVID-19	Drug: Tocilizumab Drug: Placebo	Queen's Medical Centre	Phase 3
NCT04408040	Use of Convalescent Plasma for COVID-19	COVID	Biological: Convalescent Plasma	Northside Hospital, Inc.	Phase 2
NCT04406064	Viral Specific T-cells for Treatment of COVID-19	Viral Infection	Biological: Viral Specific T-cells (VSTs)	Children's Hospital Medical Center, Cincinnati Hoxworth Blood Center	Phase 2
NCT04395222	Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation	Hematologic Malignancy Bone Marrow Transplant	Drug: Tocilizumab Drug: Fludarabine Drug: Melphalan Drug: Anti-thymocyte globulin (rabbit) Radiation: Total Body Irradiation	Weill Medical College of Cornell University	Phase 2
NCT04395079	Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies	Metastatic Malignant Female Reproductive System Neoplasm Platinum-Resistant Malignant Female Reproductive System Neoplasm Recurrent Malignant Female Reproductive System Neoplasm Refractory Malignant Female Reproductive System Neoplasm	Biological: Durvalumab Radiation: Internal Radiation Therapy Biological: Tremelimumab	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04392206	AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses	End Stage Renal Disease	Drug: Adipose Derived Mesenchymal Stem Cells	Albert Hakaïm Mayo Clinic	Phase 1
NCT04375527	Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma	Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Locally Advanced Cutaneous Melanoma Metastatic Cutaneous Melanoma Pathologic Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8 Pathologic Stage IV Cutaneous Melanoma AJCC v8 Unresectable Cutaneous Melanoma	Drug: Binimetinib Biological: Nivolumab Other: Questionnaire Administration	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04362501	Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)	Chronic Sinusitis	Biological: dupilumab Drug: placebo	Johns Hopkins University	Phase 2
NCT04356469	TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children	Hemoglobinopathy (Disorder) Severe Aplastic Anemia Bone Marrow Failure Syndrome	Biological: Haploidentical Hematopoietic Cell Transplantation	Johns Hopkins All Children's Hospital	Phase 2
NCT04350125	PRP for the Treatment of Erectile Dysfunction (ED)	Erectile Dysfunction	Biological: Autologous Platelet Rich Plasma	Mayo Clinic	Phase 1
NCT04348747	Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Triple-Negative Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8	Biological: Anti-HER2/HER3 Dendritic Cell Vaccine Drug: Celecoxib Biological: Pembrolizumab Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04340882	Phase 2 TaxRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade	Metastatic Non-Small Lung Cell Cancer Recurrent Non-Small Lung Cell Cancer Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Drug: Docetaxel Biological: Pembrolizumab Biological: Ramucirumab	Emory University National Cancer Institute (NCI) Merck Sharp & Dohme Corp.	Phase 2
NCT04323046	Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults	Glioblastoma Malignant Glioma Recurrent Glioblastoma Recurrent Malignant Glioma Recurrent Grade III Glioma Grade III Glioma	Biological: Ipilimumab Biological: Nivolumab Drug: Placebo Administration Other: Quality-of-Life Assessment Other: Questionnaire Administration	Sabine Mueller, MD, PhD Bristol-Myers Squibb Pacifi Pediatric Neuro-Oncology Consortium University of California, San Francisco	Phase 1

해외 바이오의약품 임상 현황 (2020.06.01 ~ 2020.06.07)

한국바이오의약품협회, 2020.6.9.
출처: ClinicalTrials.gov

NCT04303572	The Hemophilia Inhibitor Eradication Trial	Hemophilia A With Inhibitor	Drug: Eloctate ITI Drug: Emicizumab	Margaret Ragni Health Resources and Services Administration (HRSA) University of Pittsburgh	Phase 3
NCT04303559	The Hemophilia Inhibitor Prevention Trial	Hemophilia A Without Inhibitor	Drug: Eloctate Injectable Product Drug: Emicizumab Injection [Hemlibra]	Margaret Ragni Health Resources and Services Administration (HRSA) University of Pittsburgh	Phase 3
NCT04302324	A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab	Multiple Myeloma Refractory Multiple Myeloma Relapse Multiple Myeloma	Drug: Daratumumab Drug: Clarithromycin Drug: Pomalidomide Drug: Dexamethasone	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC	Phase 2
NCT04301778	Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Unresectable Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: SNDX-6352	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals AstraZeneca	Phase 2
NCT04256759	Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus	Pruritus	Drug: Dupilumab 300Mg Solution for Injection	Mayo Clinic Regeneron Pharmaceuticals	Phase 2
NCT04254419	Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas	High Grade Glioma	Biological: NK cells	Nationwide Children's Hospital	Phase 1
NCT04242264	Phase 2 Shigella Vaccine and Challenge	Immunisation Shigella Infection	Other: Placebo Biological: Shigella sonnei strain 53G Biological: WRSs2	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
NCT04239157	Canakinumab and Anacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia	Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Refractory Chronic Myelomonocytic Leukemia Refractory Myelodysplastic Syndrome	Biological: Canakinumab	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04230356	Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant	Allogeneic Stem Cell Transplant Viral Infection	Biological: Viral Specific T-cells (VSTs) Scheduled Biological: Viral Specific T-cells (VSTs) Treatment	Children's Hospital Medical Center, Cincinnati Hoxworth Blood Center	Phase 2
NCT04225039	Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma	Glioblastoma	Drug: INCMGA00012 Drug: INCAGN01876 Drug: SRS Procedure: Brain surgery	University of Pennsylvania Incyte Corporation	Phase 2
NCT04220684	Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Allogeneic Stem Cell Transplant Recipient Blasts 10 Percent or More of Bone Marrow Nucleated Cells Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia	Drug: Cytarabine Drug: Cytarabine Hydrochloride Drug: Decitabine Drug: Fludarabine Drug: Fludarabine Phosphate Biological: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells	Sumithira Vasu National Cancer Institute (NCI) Ohio State University Comprehensive Cancer Center	Phase 1
NCT04220008	Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma	Recurrent Aggressive Non-Hodgkin Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma Recurrent T-Cell Non-Hodgkin Lymphoma Recurrent Transformed B-Cell Non-Hodgkin Lymphoma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Busulfan Drug: Clofarabine Drug: Cyclophosphamide Drug: Gemcitabine Drug: Mycophenolate Mofetil Biological: Rituximab Drug: Tacrolimus Drug: Vorinostat	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04209686	Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma	Advanced Gastric Adenocarcinoma	Drug: Paclitaxel Drug: Olaparib Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Merck Sharp & Dohme Corp.	Phase 2
NCT04205409	Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	Recurrent Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Plasma Cell Myeloma Refractory Chronic Lymphocytic Leukemia Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Non-Hodgkin Lymphoma Refractory Plasma Cell Myeloma	Biological: Nivolumab	University of Washington National Cancer Institute (NCI) Bristol-Myers Squibb	Phase 2
NCT04199767	SMIFF Multi-Device Study 2	Mild Cognitive Impairment Cognitive Impairment	Drug: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) Drug: 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)	Wake Forest University Health Sciences	Phase 2
NCT04197219	Pembrolizumab With Axitinib in Recurrent Endometrial Cancer	Recurrent Endometrial Cancer	Drug: Pembrolizumab Drug: Axitinib	Haider Mahdi Case Comprehensive Cancer Center	Phase 2
NCT04177810	Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer	Metastatic Pancreatic Cancer	Drug: Cemiplimab Drug: Plerixafor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Genzyme, a Sanofi Company American Association for Cancer Research	Phase 2
NCT04174560	Phase I Norovirus Challenge Model	Gastroenteritis Norovirus	Biological: Norovirus GII.4 Challenge Pool	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
NCT04150640	P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric	Esophageal Adenocarcinoma Gastric Adenocarcinoma	Drug: Nal-IRI Drug: Oxaliplatin Drug: 5-FU Drug: Trastuzumab	University of Wisconsin, Madison Ipsern	Phase 2
NCT04149821	Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy	Chronic Lymphocytic Leukemia CLL Progression CLL/SLL	Drug: Umbralisib Drug: Ublituximab	Weill Medical College of Cornell University TG Therapeutics, Inc.	Phase 2

해외 바이오의약품 임상 현황 (2020.06.01 ~ 2020.06.07)

한국바이오의약품협회, 2020.6.9.
출처: ClinicalTrials.gov

NCT04140162	Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy	Multiple Myeloma	Drug: Daratumumab Drug: Lenalidomide Drug: Bortezomib Drug: Dexamethasone	University of Michigan Rogel Cancer Center Janssen Scientific Affairs, LLC	Phase 2
NCT04125719	PVSRPO in Combination With Nivolumab in Melanoma	Melanoma	Biological: PVSRPO Drug: Nivolumab	Darell Bigner Duke University Istari Oncology, Inc. Bristol-Myers Squibb	Phase 1
NCT04117087	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer	Colorectal Cancer Pancreatic Cancer	Drug: KRAS peptide vaccine Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	HLA-A2 Positive Cells Present Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04077021	First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer	Castration-Resistant Prostatic Cancer	Drug: CCW702	Calibr, a division of Scripps Research	Phase 1
NCT04073472	Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's	Crohn's Disease Fistula Anal Fistula Pouch, Ileal Pouches, Ileoanal	Drug: mesenchymal stem cells (MSCs)	The Cleveland Clinic	Phase 1
NCT04073160	TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer	Bladder Cancer	Drug: Tremelimumab Drug: Durvalumab Radiation: Bladder radiation Drug: Intravesicular Therapy	Daniel George, MD AstraZeneca Duke University	Phase 1
NCT04049383	CAR-20/19-T Cells in Pediatric Patients With Relapsed/Refractory B Cell ALL	Acute Lymphoblastic Leukemia, in Relapse Acute Lymphoblastic Leukemia With Failed Remission Acute Lymphoblastic Leukemia Recurrent Acute Lymphoblastic Leukemia Not Having Achieved Remission Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia	Biological: CAR-20/19-T cells	Medical College of Wisconsin Children's Hospital and Health System Foundation, Wisconsin	Phase 1
NCT04030052	Emicizumab PUPs and Nuwiq ITI Study	Hemophilia A	Drug: Nuwiq (low dose protocol) Drug: Emicizumab Drug: Nuwiq (Atlanta protocol)	Emory University	Phase 3
NCT04024878	NeoVax With Nivolumab in Patients With Ovarian Cancer	Ovarian Cancer	Drug: Nivolumab Biological: NeoVax Procedure: Core Needle Biopsy	Dana-Farber Cancer Institute United States Department of Defense	Phase 1
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2
NCT03941769	Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant	Acute Myeloid Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Cord Blood Transplant Recipient Myelodysplastic Syndrome Myeloproliferative Neoplasm	Biological: Recombinant Interleukin-7	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT03917407	DUR-928 in Patients With Alcoholic Hepatitis	Alcoholic Hepatitis	Drug: DUR-928 (Moderate AH) Drug: DUR-928 (Severe AH)	Craig James McClain National Institute on Alcohol Abuse and Alcoholism (NIAAA) University of Louisville	Phase 2
NCT03862079	Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics	Graft-versus-host Disease Prevention	Other: Best Practice Procedure: Fecal Microbiota Transplantation Drug: Nystatin Drug: Piperacillin-Tazobactam	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT03617445	Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients	Clostridium Difficile Infection Recurrence	Drug: FMT enema Drug: Oral Vancomycin Drug: FMT enema placebo Drug: Oral Vancomycin placebo	University of Wisconsin, Madison	Phase 2
NCT03527108	Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC	Non Small Cell Lung Cancer	Drug: Nivolumab, ramucirumab Drug: Nivolumab	Fox Chase Cancer Center Bristol-Myers Squibb Eli Lilly and Company	Phase 2
NCT04412668	Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19	SARS-CoV-2 (COVID-19) Severe Pneumonia	Drug: ATYR1923 1 mg/kg Drug: ATYR1923 3 mg/kg Drug: Placebo	aTyr Pharma, Inc.	Phase 2
NCT04387084	Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy	Advanced Malignant Skin Neoplasm Metastatic Malignant Skin Neoplasm	Drug: Atezolizumab Drug: Avelumab Biological: Cemiplimab Biological: Durvalumab Biological: Nivolumab Biological: Pembrolizumab Other: Quality-of-Life Assessment Other: Short-Term Fasting	University of Southern California National Cancer Institute (NCI)	Phase 1
NCT04313504	Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC	Head and Neck Cancer	Drug: Niraparib Drug: Dostarlimab	Trisha Wise-Draper Tesaro, Inc. University of Cincinnati	Phase 2
NCT03768310	CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)	Non-hodgkin Lymphoma Acute Lymphoblastic Leukemia	Biological: CD19.CAR-multiVST for Group A Biological: CD19.CAR-multiVST for Group B	Baylor College of Medicine The Methodist Hospital System Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1
NCT04340258	Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC	HNSCC	Device: Cesium-131 Drug: Pembrolizumab	University of Cincinnati IsoRay Medical, Inc.	Phase 1 Phase 2
NCT04396535	Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer	Advanced Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Drug: Bintrafusp Alfa Drug: Docetaxel	Mayo Clinic National Cancer Institute (NCI)	Phase 2
NCT04224701	A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults	HIV Infections	Biological: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted Biological: Placebo	International AIDS Vaccine Initiative GlaxoSmithKline Rockefeller University George Washington University VU University Medical Center	Phase 1
NCT04411654	Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)	Gaucher Disease, Type 2	Biological: PR001	Prevail Therapeutics	Phase 1 Phase 2

해외 바이오의약품 임상 현황 (2020.06.01~2020.06.07)

한국바이오의약품협회, 2020.6.9.
출처: ClinicalTrials.gov

NCT04408625	Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)	Frontotemporal Dementia	Biological: PR006	Prevail Therapeutics	Phase 1 Phase 2
NCT04406623	Phase 1 Study of SL-172154 (SIRPa-Fc-CD40L) in Subjects With Ovarian Cancer	Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma	Drug: SL-172154	Shattuck Labs, Inc.	Phase 1
NCT04272645	Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer	Prostate Cancer	Drug: Abemaciclib 200 MG Drug: Atezolizumab 1200 MG in 20 ML Injection Drug: Abemaciclib 150 MG	University of Michigan Rogel Cancer Center	Phase 2
NCT04270175	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab	Amyloid AL Amyloidosis Refractory AL Amyloidosis	Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC	Phase 2
NCT04212091	Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants	HIV Infections	Biological: PGT121.414.LS Biological: VRC07-523LS	National Institute of Allergy and Infectious Diseases (NIAID) HIV Vaccine Trials Network HIV Prevention Trials Network	Phase 1
NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant Androgen-Resistant Prostatic Neoplasms Castration Resistant Prostatic Neoplasms Prostatic Cancer, Castration-Resistant	Drug: AB928 Drug: Zimberelimab Drug: AB680 Drug: Enzalutamide Drug: Docetaxel	Arcus Biosciences, Inc.	Phase 1 Phase 2
NCT04322708	A Study of Antolimab (AK002) in Patients With Active Eosinophilic Esophagitis	Eosinophilic Esophagitis	Other: Placebo Drug: antolimab (AK002)	Allakos, Inc.	Phase 2 Phase 3
NCT04398433	INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)	Respiratory Papillomatosis	Drug: INO-3107 Device: COLLECTRA™ 2000	Inovio Pharmaceuticals	Phase 1 Phase 2
NCT04300647	A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer	Cervical Cancer	Drug: Tiragolumab Drug: Atezolizumab	Hoffmann-La Roche	Phase 1 Phase 2
NCT04219254	A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Solid Tumor, Adult	Biological: BI-1206	BiolInvent International AB	Phase 1 Phase 2
NCT04418765	A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients That Are Not Helped by Previous Preventive Treatments	Migraine	Drug: Eptinezumab 100 mg Drug: Eptinezumab 300 mg Drug: Placebo	H. Lundbeck A/S	Phase 3
NCT04392154	Long-term Safety and Efficacy Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis	Atopic Dermatitis	Biological: Lebrikizumab	Dermira, Inc. Eli Lilly and Company	Phase 3
NCT04322604	A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)	Eosinophilic Gastritis Eosinophilic Duodenitis	Drug: antolimab (AK002) Other: Placebo	Allakos, Inc.	Phase 3
NCT04295538	Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)	Spinal Cord Injury (SCI)	Drug: Elezanumab Drug: Placebo	AbbVie	Phase 2
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3
NCT04416451	Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma	Marginal Zone Lymphoma	Drug: Rituximab Drug: Venetoclax	Memorial Sloan Kettering Cancer Center AbbVie	Phase 2
NCT04380805	A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer	Recurrent Cervical Cancer Metastatic Cervical Cancer	Biological: AK104	Akeso Akesobio Australia Pty Ltd	Phase 2
NCT04171531	Sling vs Botox for Mixed Incontinence	Urinary Incontinence, Stress Urinary Incontinence, Urge	Drug: Botox® injection Device: Mid-urethral sling	NICHD Pelvic Floor Disorders Network Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Women and Infants Hospital of Rhode Island Duke University University of Pennsylvania University of Pittsburgh University of California, San Diego Kaiser Permanente University of Texas Southwestern Medical Center University of Alabama at Birmingham RTI International	Phase 3
NCT04209660	Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Adenoid Cystic Carcinoma Salivary Gland Cancer	Drug: Lenvatinib Drug: Pembrolizumab	Memorial Sloan Kettering Cancer Center Merck Sharp & Dohme Corp. Eisai Inc.	Phase 2

해외 바이오의약품 임상 현황 (2020.06.01~2020.06.07)

한국바이오의약품협회, 2020.6.9.
출처: ClinicalTrials.gov

○ 영국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04419688	A First in Human Study of STT-5058, an Antibody That Binds ApoC3	Hypertriglyceridemia	Drug: STT-5058 Drug: Placebo	Staten Biotechnology BV	Phase 1
NCT04300647	A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer	Cervical Cancer	Drug: Tiragolumab Drug: Atezolizumab	Hoffmann-La Roche	Phase 1 Phase 2
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3
NCT04418765	A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients That Are Not Helped by Previous Preventive Treatments	Migraine	Drug: Eptinezumab 100 mg Drug: Eptinezumab 300 mg Drug: Placebo	H. Lundbeck A/S	Phase 3

○ 프랑스 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04266301	Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: MBG453 Drug: Azacitidine Drug: Placebo	Novartis Pharmaceuticals Novartis	Phase 3
NCT04407689	InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort	COVID-19 Lymphocytopenia	Drug: Interleukin-7 Drug: Placebo	Revimmune University Hospital, Limoges Amarex Clinical Research	Phase 2
NCT04300647	A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer	Cervical Cancer	Drug: Tiragolumab Drug: Atezolizumab	Hoffmann-La Roche	Phase 1 Phase 2
NCT04239196	Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA	Giant Cell Arteritis Optic Ischaemic Neuropathy	Drug: tocilizumab and IV steroids combination Other: IV steroids combination alone	Centre Hospitalier National d'Ophthalmologie des Quinze-Vingts Roche Chugai	Phase 2
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3
NCT04418765	A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients That Are Not Helped by Previous Preventive Treatments	Migraine	Drug: Eptinezumab 100 mg Drug: Eptinezumab 300 mg Drug: Placebo	H. Lundbeck A/S	Phase 3
NCT04392154	Long-term Safety and Efficacy Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis	Atopic Dermatitis	Biological: Lebrikizumab	Dermira, Inc. Eli Lilly and Company	Phase 3

○ 독일 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT00916201	Evaluation Study of New Compounds With Potential Use in Schizophrenia	Schizophrenia	Drug: URB597 Drug: intranasal Insulin Drug: Cannabidiol CR	Central Institute of Mental Health, Mannheim Max-Planck Institute for Metabolism Research	Phase 1
NCT04195373	A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract	Gastrointestinal Cancer	Biological: TMV-018 + 5-FC Biological: TMV-018 + anti-PD-1 Biological: TMV-018 + 5-FC + anti-PD-1	Themis Bioscience GmbH Assign Data Management and Biostatistics GmbH SSS International Clinical Research GmbH	Phase 1
NCT04309409	Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma	Malignant Melanoma Stage II	Drug: Nivolumab	University Hospital, Essen	Phase 3
NCT04418765	A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients That Are Not Helped by Previous Preventive Treatments	Migraine	Drug: Eptinezumab 100 mg Drug: Eptinezumab 300 mg Drug: Placebo	H. Lundbeck A/S	Phase 3
NCT04392154	Long-term Safety and Efficacy Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis	Atopic Dermatitis	Biological: Lebrikizumab	Dermira, Inc. Eli Lilly and Company	Phase 3
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3

해외 바이오의약품 임상 현황 (2020.06.01 ~ 2020.06.07)

한국바이오의약품협회, 2020.6.9.
출처: ClinicalTrials.gov

○ 중국 16건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04407741	Phase I/II Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	Solid Tumor Lymphoma	Drug: SHR2554+SHR1701 Drug: SHR1701	Chinese PLA General Hospital	Phase 1 Phase 2
NCT03460795	Safety and Efficacy Study of Co-transferring of Mesenchymal Stem Cell and Regulatory T Cells in Treating End-stage Liver Disease	Liver Cirrhosis	Biological: MSC and Tregs	Nanjing Medical University	Phase 1 Phase 2
NCT04418401	Study on the Safety and Efficacy of Donafenib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients	Hepatocellular Carcinoma	Drug: Donafenib and anti-PD-1 antibody	Zhejiang University	Phase 1
NCT04417166	Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma	Lymphoma, Extranodal NK-T-Cell	Drug: Pembrolizumab Radiation: Involved Field Radiation Therapy	International Extranodal Lymphoma Study Group (IELSG)	Phase 2
NCT04415385	The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma	Pancreatic Cancer	Drug: Camrelizumab Drug: Apatinib	Zhejiang Cancer Hospital	Phase 2
NCT04400383	Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors	Solid Tumor Gastric Cancer Pancreatic Adenocarcinoma	Drug: AB011 Injection	Carsgen Therapeutics, Ltd. Shanghai East Hospital	Phase 1
NCT04399785	Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC	Head and Neck Squamous Cell Carcinoma	Other: Camrelizumab and SBRT	Xingchen Peng Jiangsu HengRui Medicine Co., Ltd. West China Hospital	Phase 2
NCT04387500	Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma	Carcinoma, Renal Cell Fumarate Hydratase Deficiency Immunotherapy	Drug: Sintilimab injection	West China Hospital	Phase 2
NCT04385173	Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma	Recurrent Glioblastoma Refractory Glioblastoma	Drug: B7-H3 CAR-T Drug: Temozolomide	Second Affiliated Hospital, School of Medicine, Zhejiang University BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.	Phase 1
NCT04126044	A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS	Pharmacokinetics	Drug: PF-06439535 (CN) Drug: bevacizumab - EU	Pfizer	Phase 1
NCT03217032	Lentiviral FVIII Gene Therapy	Hemophilia A	Biological: YUVA-GT-F801	Shenzhen Geno-Immune Medical Institute	Phase 1
NCT04406129	Effect of Gut Microbiome Restoration on Primary Hypertension Via FMT	Hypertension	Biological: FMT capsules Other: Placebo capsules	Chinese Academy of Medical Sciences, Fuwai Hospital National Natural Science Foundation of China	Phase 1 Phase 2
NCT04405505	A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)	Triple Negative Breast Cancer	Drug: TQB2450 Drug: Anlotinib Drug: Paclitaxel for Injection (albumin bound)	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3
NCT04401800	Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma	Hepatocellular Carcinoma Unresectable Hepatocellular Carcinoma Metastatic Hepatocellular Carcinoma	Drug: Lenvatinib Drug: Tislelizumab	BeiGene	Phase 2
NCT04060888	A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus	Lupus Erythematosus, Systemic	Drug: Ustekinumab (approximately 6 mg/kg) Drug: Ustekinumab 90 milligram (mg) Drug: Placebo	Janssen Research & Development, LLC	Phase 3
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3

○ 일본 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04417192	Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer	Ovarian Cancer	Drug: Olaparib Drug: Pembrolizumab	National Cancer Center Hospital East Merck Sharp & Dohme Corp.	Phase 2
NCT04384081	A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2	Healthy	Drug: BI 456906 Drug: Placebo	Boehringer Ingelheim	Phase 1
NCT04354480	A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older	Healthy	Biological: RSV Vaccine Other: Placebo	Janssen Pharmaceutical K.K.	Phase 1
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3